Arcutis Posts 290% EPS Surprise with $129.5M Q4 Revenue
Arcutis Biotherapeutics reported adjusted Q4 EPS of $0.13, beating estimates by $0.10 and reversing a year-ago $0.09 per-share loss. The company generated $129.5 million in revenue, up 81% year-over-year and 11.9% above consensus.
1. Q4 Earnings Beat
Arcutis delivered adjusted earnings per share of $0.13 for the quarter ended December 2025, reversing a prior-year loss of $0.09 and outperforming consensus by 290%. This marks the fourth consecutive quarter of EPS surprises and underscores improved operational efficiency.
2. Revenue Growth Surge
The company posted $129.5 million in Q4 revenue, an 81% increase from $71.36 million a year earlier and 11.9% above analyst forecasts. Continued uptake of its dermatology portfolio drove the top-line strength.
3. YTD Stock Performance
Despite robust results, Arcutis shares have declined approximately 7.1% year-to-date, underperforming the S&P 500’s 0.7% gain. Investor focus remains on whether earnings momentum can translate into sustained share appreciation.
4. Forward Outlook and Guidance
Current consensus forecasts call for Q1 revenue of $94.6 million with a loss of $0.02 per share, and full-year EPS of $0.38 on $470.02 million in revenue. Management commentary on pipeline progress and cost control will be key drivers for upcoming guidance revisions.